U.S. markets closed

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.8500-0.2400 (-4.72%)
At close: 4:00PM EDT
4.8600 +0.01 (0.21%)
After hours: 07:59PM EDT
Sign in to post a message.
  • T
    Tony
    Share price and volume are artificially pressed by GS to arrive to the final BO offer price of $38
  • D
    Donny
    Dr. Simantov, former Pfizer VP of Oncology, will support Clovis’ key strategic priority to continue to advance Rubraca’s pipeline into a potentially broader label. The new indication will be a result of Topline data for Rubraca monotherapy arm vs placebo in the anticipated Athena trial results. The trial results are expected to support a sNDA for Front-Line, Newly-Diagnosed Advanced Ovarian Cancer treatment.
    Bullish
  • C
    Chevy
    not sure if you saw it but AMGN gave some private biotech 900MM upfront buyout and a CRV for 1.6B today. Didn't remember what they did.
  • D
    Donny
    Rumor on the street is that CLVS is about to advance the Rubraca pipeline into a potentially broader label. Rubraca already has multiple fda approved indications. Investors are expecting Athena trial results soon. Do we get a sneak peek on August 4th? I wouldn’t bet against it.

    Athena is all about Front-Line, Newly-Diagnosed Advanced Ovarian Cancer treatment.

    Topline data for Rubraca monotherapy arm vs placebo expected 2H 2021; intended to support a supplemental New Drug Application filing (sNDA)

    Buy the rumor. Sell the news.
    Bullish
  • M
    Morgan
    The Novartis CEO also said that the company's oncology drug division earnings were down 30% year over year for the quarter ending in June. BMY also said there earnings were down 15%. But if you think about this it explains in part the nuking of oncology biotech stocks by the street because there has been no positive earnings visability until now. The NVS CEO said that sales will return to normal this next quarter and are expected to ramp up from here. Oncology sites have been ghost towns this Spring but now people are being worked up and staged (needing later stage therapy thanks to missing 18 months of treatment). I think the whole sector is poised to rebound in the next weeks. If there is one more shake out of CLVS with earnings I will be adding more. Now is not the time to give up-- rather the opposite!
  • k
    keith
    remember clvs loves giving back its gains , you can make lots of money shorting this stock on every pop
  • D
    David
    Xbi down driving down clvs.l on low volume for clvs. RSI is oversold. Termites on this board are near all time highs. How many times in the past when the rodents dominate this board and this thing goes up 30-50% without warning or reason. It will happen again in the near future.
  • J
    Jerry
    Clovis will not have revenue of over 45million. They will be between 34 to 38 million yet again and again. They will need to show expenses lower then 55 million for the quarter. Problem is New trials began and need money.
    Bearish
  • H
    Harry
    Today AMGN put up a 2.5B price tag on a P1 asset for mCRPC from Teneobio. So what's wrong with CLVS with a successful P3 status for same indication. Any thoughts? TIA
  • D
    Donny
    Big dip on low volume. Nice stop loss raid. doesn't look like it was successful!
    Bullish
  • E
    Eugene
    OK, the bashers are hedge fund interns who are tasked to distort the message board. They are trying hard to please their employers and hope to get hired.
  • A
    Annie
    Bad day for the market but a good day for clvs. hopefully this is beginning to turn around.
  • D
    Donny
    Tell tell signs that it’s time to cover. 700,000 shares available to short (that’s high) and a low .88% borrow rate is a good sign that smart money has already covered. There is not a lot of demand to sell these shares short.
    Bullish
  • l
    leinheiser
    If you’re looking for a short and sweet guide to the day’s biggest news, I recommend (http://Pick-stocks.com). They breakdown the most important pre-market news and it only takes a few minutes to read.
  • L
    LookinNListenin
    5.03, at support, 5.19 ± 0.176 type double, strength 8
    Support Below : -4.1% at 4.83 ± 0.164 type single, strength 1
    Resistance Above : +15.8% at 5.83 ± 0.198 type triple+, strength 10
    I think we will take out the overhead resistance next week, specially if the tech sells off and money moves into biotech.
    Bullish
  • J
    Jerry
    Follow Keith and be rewarded
  • B
    BoxFan
    Novartis is hoping to cement an early lead in a potential $10bn market for a new type of cancer treatment, called novel radioligand therapy, after positive results from its trials. Vas Narasimhan, Novartis’s chief executive, said the pharmaceutical company has large-scale manufacturing capacity and relationships with hospitals, which will have to invest to adapt to deliver the treatments, that would lead to a “virtuous cycle” where competitors find it harder to displace the company’s dominance. “We believe it could be, in the coming decade, a $10bn plus market,” he told the Financial Times.
  • A
    Annie
    talked to my broker. He said poor earnings due to covid are expected by everyone. the stock will move up upon the release of earnings. long term, I believe we all make big money.
    Bullish
  • D
    Donny
    Why you should avoid buying short term CLVS call options - Shorting Without Failing to Deliver

    We all know about naked shorting and how it can be used to create a false selling pressure that causes a stock to decline in SP or remain relatively flat. There is another form of short selling, which doesn’t require borrowed shares. The market maker can sell calls an buy puts. Both can cause selling pressure by creating a negative delta and the MM profits from the puts when SP drops. Neither of these positions requires borrowing stock or naked shorting "failing to deliver" stock. How many times have we seen the SP be driven up close to a call option strike price only to see it get walked back down so those calls are OTM?

    I know this won’t prevent anyone from gambling with call options. At least it gives investors an opportunity to trade around their core positions and accumulate. If you know the game, you know how to play your hand. Just sayin’…

    When we see this behavior change and call options are t being pumped, we know a big move is anticipated
    Bullish
  • D
    Donny
    If you are short CLVS, are you holding through earnings report?
    Bullish